Acrivon's Phase 2b Endometrial Cancer Data Triggers Unexpected Market Pullback

Acrivon Therapeutics (ACRV) experienced a sharp stock decline despite releasing encouraging Phase 2b trial results for its lead drug candidate ACR-368. The biotech company’s shares plummeted 28.71% to $2.1044, representing an $0.8456 drop, creating a stark contrast between clinical progress and investor sentiment.

Clinical Data Shows Promise While Market Sells Off

The Phase 2b endometrial cancer trial results revealed solid efficacy metrics. Patients with serous-type endometrial cancer demonstrated a 52% confirmed overall response rate among those with two or fewer prior treatment lines, while biomarker-positive patients achieved a notably higher 67% response rate. These figures represented meaningful progress for ACR-368 development. Yet rather than rallying on the positive outcomes, Acrivon’s stock suffered significant selling pressure immediately following the data release.

Trading Activity and Market Reaction

Trading activity surged well above average daily volumes, signaling intense investor focus. ACRV opened near $2.95 on the announcement day, eventually dipping to an intraday low of approximately $1.98 while reaching an intraday peak close to $3.12—a wide range reflecting sharp divergence in how market participants interpreted the results. The stock’s 52-week trading range spans $1.05 to $8.00, underscoring the volatility inherent in biotech development-stage companies.

Expansion Plans to Accelerate Patient Recruitment

To capitalize on the trial momentum, Acrivon announced plans to expand the Phase 2b study into European Union markets, aiming to expedite patient enrollment. This geographic expansion represents the company’s strategy to broaden its clinical footprint and strengthen its regulatory pathway. The shares trade on Nasdaq, where biotech volatility often reflects both clinical progress and market sentiment shifts regarding development timelines and competitive positioning.